Last week, our client Breye Therapeutics announced the appointment of Dr Peter Adamson as Chief Scientific Officer (CSO) and Gabriela Burian as a new member of its Board of Directors. It also launched its new website and LinkedIn page. Breye is a clinical-stage biopharmaceutical company developing novel, oral ophthalmology drugs to address the needs of […]
More than one hundred industry executives and experts provided insight into what to expect for the year ahead. Here’s what we’ve read so far… Technological Advances Today’s article explores the technological advances expected during 2023. Developments in data science and molecular biology drive expectations – for another year of breakthrough innovation in human therapeutics. However, […]
Copenhagen, Denmark – Novo Holdings, a leading international life sciences investor, today announced that it has invested in Sound Bioventures Fund I as cornerstone investor in the first close of EUR 110 million. Sound Bioventures will be investing in private biotech companies and will focus on companies with assets in clinical or late pre-clinical stages, primarily […]
